Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy

Journal of the Medical Association of Thailand

Volumn 95, Issue 2, 2012, Pages 163-169

  Mankhatitham, Wiroj ^a   Luaengniyomkul, Aroon ^a   Manosuthi, Weerawat ^a  

^a Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

HIV; Lipid profile change; Non nucleoside reverse transcriptase inhibitors; Thai

Indexed keywords

CHOLESTEROL; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS;

ADOLESCENT; ADULT; BENZOXAZINES; CHOLESTEROL, HDL; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIPIDS; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THAILAND; TRIGLYCERIDES; TUBERCULOSIS; YOUNG ADULT;

EID: 84858062153     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitorassociated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
2. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70.
3. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-5.
4. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapinecontaining antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14.
5. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clin Trials 2003; 4: 29-36.
6. Bennett MT, Johns KW, Bondy GP. Current and future treatment of HIV-associated dyslipidemia. Future Lipidol 2008; 3: 175-88.
7. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
8. DAD Study Group, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
9. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitorbased antiretroviral therapy. Antivir Ther 2007; 12: 1247-54.
10. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirikul W, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitorbased regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48: 1752-9.
11. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
12. Padmapriyadarsini C, Ramesh KS, Terrin N, Narendran G, Menon PA, Ramachandran G, et al. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Clin Infect Dis 2011; 52: 540-6.
13. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008; 47: 304-11.
14. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al. Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585-91.
15. Tohyama J, Billheimer JT, Fuki IV, Rothblat GH, Rader DJ, Millar JS. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis 2009; 204: 418-23.
16. Franssen R, Sankatsing RR, Hassink E, Hutten B, Ackermans MT, Brinkman K, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009; 29: 1336-41.
17. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-41.
18. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviraltherapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.